US3574850A - Medicament having particularly an antifungal bactericidal and bacteriostatic activity - Google Patents
Medicament having particularly an antifungal bactericidal and bacteriostatic activity Download PDFInfo
- Publication number
- US3574850A US3574850A US871753A US3574850DA US3574850A US 3574850 A US3574850 A US 3574850A US 871753 A US871753 A US 871753A US 3574850D A US3574850D A US 3574850DA US 3574850 A US3574850 A US 3574850A
- Authority
- US
- United States
- Prior art keywords
- solution
- ipl
- butyric acid
- bactericidal
- bacteriostatic activity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 230000003385 bacteriostatic effect Effects 0.000 title abstract description 11
- 230000000844 anti-bacterial effect Effects 0.000 title abstract description 10
- 230000000843 anti-fungal effect Effects 0.000 title 1
- 229940121375 antifungal agent Drugs 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract description 14
- 230000002421 anti-septic effect Effects 0.000 abstract description 7
- 239000007864 aqueous solution Substances 0.000 abstract description 6
- 230000001532 anti-fungicidal effect Effects 0.000 abstract description 3
- 230000000144 pharmacologic effect Effects 0.000 abstract description 3
- 239000002904 solvent Substances 0.000 abstract description 3
- KPJKMUJJFXZGAX-UHFFFAOYSA-N 2-chloropropan-2-ylbenzene Chemical compound CC(C)(Cl)C1=CC=CC=C1 KPJKMUJJFXZGAX-UHFFFAOYSA-N 0.000 abstract 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 41
- 244000005700 microbiome Species 0.000 description 14
- 238000010790 dilution Methods 0.000 description 10
- 239000012895 dilution Substances 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 241000588724 Escherichia coli Species 0.000 description 8
- 239000002609 medium Substances 0.000 description 8
- -1 alkyl dimethyl benzyl ammonium chloride Chemical compound 0.000 description 7
- 229960000686 benzalkonium chloride Drugs 0.000 description 6
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 229920001817 Agar Polymers 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 239000008272 agar Substances 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- 241000194032 Enterococcus faecalis Species 0.000 description 4
- 241000194017 Streptococcus Species 0.000 description 4
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 239000000470 constituent Substances 0.000 description 4
- 235000002906 tartaric acid Nutrition 0.000 description 4
- 239000011975 tartaric acid Substances 0.000 description 4
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 241000588769 Proteus <enterobacteria> Species 0.000 description 3
- 241000588767 Proteus vulgaris Species 0.000 description 3
- 241000191967 Staphylococcus aureus Species 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000002949 hemolytic effect Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000011835 investigation Methods 0.000 description 3
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 229940007042 proteus vulgaris Drugs 0.000 description 3
- NLHHRLWOUZZQLW-UHFFFAOYSA-N Acrylonitrile Chemical compound C=CC#N NLHHRLWOUZZQLW-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 244000063299 Bacillus subtilis Species 0.000 description 2
- 235000014469 Bacillus subtilis Nutrition 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 241000588748 Klebsiella Species 0.000 description 2
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 2
- 241000193996 Streptococcus pyogenes Species 0.000 description 2
- 230000037006 agalactosis Effects 0.000 description 2
- 230000001476 alcoholic effect Effects 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 235000019658 bitter taste Nutrition 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000004040 coloring Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- LDHQCZJRKDOVOX-NSCUHMNNSA-N crotonic acid Chemical compound C\C=C\C(O)=O LDHQCZJRKDOVOX-NSCUHMNNSA-N 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- NDVLTYZPCACLMA-UHFFFAOYSA-N silver oxide Chemical compound [O-2].[Ag+].[Ag+] NDVLTYZPCACLMA-UHFFFAOYSA-N 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 229940098465 tincture Drugs 0.000 description 2
- LDHQCZJRKDOVOX-UHFFFAOYSA-N trans-crotonic acid Natural products CC=CC(O)=O LDHQCZJRKDOVOX-UHFFFAOYSA-N 0.000 description 2
- SLRMQYXOBQWXCR-UHFFFAOYSA-N 2154-56-5 Chemical compound [CH2]C1=CC=CC=C1 SLRMQYXOBQWXCR-UHFFFAOYSA-N 0.000 description 1
- OALHHIHQOFIMEF-UHFFFAOYSA-N 3',6'-dihydroxy-2',4',5',7'-tetraiodo-3h-spiro[2-benzofuran-1,9'-xanthene]-3-one Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(I)=C(O)C(I)=C1OC1=C(I)C(O)=C(I)C=C21 OALHHIHQOFIMEF-UHFFFAOYSA-N 0.000 description 1
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
- 101100173447 Caenorhabditis elegans ger-1 gene Proteins 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 239000007868 Raney catalyst Substances 0.000 description 1
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 1
- 229910000564 Raney nickel Inorganic materials 0.000 description 1
- 241000235527 Rhizopus Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000193985 Streptococcus agalactiae Species 0.000 description 1
- 206010048222 Xerosis Diseases 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000007859 condensation product Substances 0.000 description 1
- RKHQGWMMUURILY-UHRZLXHJSA-N cortivazol Chemical compound C([C@H]1[C@@H]2C[C@H]([C@]([C@@]2(C)C[C@H](O)[C@@H]1[C@@]1(C)C2)(O)C(=O)COC(C)=O)C)=C(C)C1=CC1=C2C=NN1C1=CC=CC=C1 RKHQGWMMUURILY-UHRZLXHJSA-N 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- RAGZEDHHTPQLAI-UHFFFAOYSA-L disodium;2',4',5',7'-tetraiodo-3-oxospiro[2-benzofuran-1,9'-xanthene]-3',6'-diolate Chemical compound [Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(I)=C([O-])C(I)=C1OC1=C(I)C([O-])=C(I)C=C21 RAGZEDHHTPQLAI-UHFFFAOYSA-L 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- LQZZUXJYWNFBMV-UHFFFAOYSA-N dodecan-1-ol Chemical compound CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 description 1
- JRBPAEWTRLWTQC-UHFFFAOYSA-N dodecylamine Chemical compound CCCCCCCCCCCCN JRBPAEWTRLWTQC-UHFFFAOYSA-N 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 229910001923 silver oxide Inorganic materials 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- An antiseptic composition comprising an aqueous solution of dodecyloxypropylamine-B-butyric acid, dodecylaminopropylamino-[i-butyric acid and an alkyl dimethyl benzyl ammonium chloride, said alkyl having from 8 to 18 carbon atoms, in a weight ratio of 1 to 1 to 0.5, in a pharmacological solvent medium.
- the antiseptic composition of the invention has an antifungicidal, bactericidal and bacteriostatic activity.
- Dodecyloxypropylamino-B-butyric acid is the compound of the formula:
- This acid can be prepared by condensing lauryl alcohol with acrylonitrile, reducing the condensation product to the amine and adding crotonic acid to the primary amino group.
- dodecylaminopropylamino-B-butyric acid is the compound of the formula: I
- 1 mol. of dodecylamine can be heated to '60 to 70 C., with 1 mol. of acrylonitrile while stirring constantly for 20 minutes.
- the mixture is kept for 6 hours at 100 C., then the product is subjected to a hydrogenation in the presence of Raney nickel and ammonia at 130 to 140 C. and under a hydrogen pressure of 150 atm., for 2 hours at the start of ice the operation in order to obtain monododecyl-1,3-arninopropylamine.
- the crude product is subjected to fractionated distillation.-
- the desired product is mixed, in equi-molecular proportions, with crotonic acid, with constant stirring at C.
- the product is dissolved in methyl ethyl ketone on a boiling water bath.
- the dodecylaminopropylamino-B-butyric acid crystallises on cooling. This is centrifuged and evaporated.
- the composition can optionally contain, as a third principle, an alkyl dimethyl benzyl ammonium chloride.
- alkyl dimethyl benzyl ammonium chloride are disclosed in the United States Pharmacopeia (USP XVI) under the name of benzalkoniurn chloride. They are quaternary ammonium salts containing a benzyl radical, two methyl radicals and a C8H17 to C1gH37 alkyl radical. They exist in the form of amorphous white powders or yellowish gelatinous masses. They have in aromatic odour and a very bitter taste, and are very soluble in water, alcohol, acetone, practically insoluble in ether and slightly soluble in benzene.
- composition provided by the invention may be in the form of an aqueous solution but, in this case, having regard to the low solubility of same of the constituents (and particularly of dodecyloxypropylamino-fl-butyric acid) in Water, the solubilisation is improved by including a physiologically acceptable acid, for example, tartaric acid.
- the composition may alternatively be in the form of an alcoholic tincture, ointment, gel, milk, liquid, soap, ovule, collutory, nasal, drop or collyrea, etc.
- proportions of the various constituents occurring in the composition can be varied up to the limits imposed by the solubility, but generally preference is given to proportions in the region of 1% of each of the acids and about 0.5% for the benzalkonium chloride.
- Microorganisms used A 1% +B 1% +C 0.5
- Bacteriostatic and bactericidal power by dilution in liquid medium In order to evaluate the bacteriostatic and bactericidal power, a method of dilution in culture broth was used, the solution being distributed in tubes. The first dilution was a 25% dilution and the inhibition after 24 hours in the oven is evaluated.
- liquid Sabouraud medium was used as culture medium, and also a method of dilution in liquid medium. Cultivation took place for eight days at 24 C.
- EXAMPLE 1 An antiseptic was prepared in the form of an aqueous solution, having the following composition:
- Dodecyloxypropylamino-fi-butyric acid 1 g.
- Dodecylaminopropylamino-fi-butyric acid 1 g.
- Benzalkonium chloride 0.50 g.
- Dodecyloxypropylamino-lS-butyric acid 1 g.
- Dodecylaminopropylamino-fi-butyric acid 1 g.
- Benzalkonium chloride 0.50 g.
- Erythrosine I tetraiodofluorescein: 0.05 g. Tartaric acid q.s. for pH 4.20
- Solution B which is a 1% solution of dodecylaminopropylamino-fl-butyric acid
- Solution BC comprising 1% of dodecylaminopropylaminop-butyric acid and 0.50% of benzalkonium chloride, this solution being at pH 4.20;
- Solution C formed by a 0.50% benzalkonium chloride solution.
- results set out in the following table are expressed in cc. of initial solution contained in 1 cc. or agar medium. For example, taking into account successive dilutions, there is observed a bacteriostatic activity with 0.001 cc. of solution per cc. of agar, that is to say, a ratio of 1:1000.
- the product to be studied was diluted beforehand in sterile distilled water and the solution obtained was added to a saline peptone broth slightly buttered to pH 7, the broth having been seeded beforehand with a culture of 15/16 hours at 37 C. of the microorganism, diluted to 1/ 10,000.
- the contact between the solution and the microorganism was one hour at ambient temperature. At the end of this period, the number of surviving microorganisms were counted, the counting being effected by placing on agar and reading the colonies which have appeared 15/28 hours after being in the oven at 37 C.
- the microorganisms investigated were of the same type as those which were used in the comparative study of the bacteriostatic activity The concentration for which it was shown that only 1% of the microorganisms survived was considered as appreciable activity.
- the concentrations given in the following table are expressed in cc. of initial solution in 1 cc. of medium; for example, if a solution with a dilution of 1/ 100 is still active, the notation is 0.001/ cc. that is to say, a ratio of 1:1000.
- Microorganisms 1 2 3 4 5 6 Solution ABC *1/200 1/100 1/20 1/200 *1/200 1/200 Solution B 1/200 1/10-1/20 1/50-1/100 *1/200 1/100 1/100 Solution BC *1/200 1/100 1/20 *1/200 1/200 1/200 Solution C *1/200 1/100 1/50-1/100 1/100 "1/200 1/50 The products were not tested at higher dilutions.
- the solution C has an activity much less than that of the three other solutions against Proteus vulgaris.
- An antiseptic composition comprising an aqueous solution of dodecyloxypropylamino-;8-butyric acid, dodecylaminopropylamino-[i-butyric acid and alkyl dimethyl benzyl ammonium chloride, said alkyl having from 8 to 18 carbon atoms, in a Weight ratio of about 1 to 1 to 0.5 and tartaric acid sufficient to give a pH in said solution of about 4.2, in a pharmacological solvent media.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Medicinal Preparation (AREA)
Abstract
AN ANTISEPTIC COMPOSITION COMPRISING AN AQUEOUS SOLUTION OF DODECYLOXYPROPYLAMINE-B-BUTYRIC ACID, DODECYLAMINOPROPYLAMINO-B-BUTYRIC ACID AND AN ALKYL DIMETHYL BENZYL CHLORIDE, SAID ALKYL HAVING FROM 8 TO 18 CARBON ATOMS, IN A WEIGHT RATIO OF 1 TO 1 TO 0.5, IN A PHARMACOLOGICAL SOLVENT MEDIUM. THE ANTISEPTIC COMPOSITION OF THE INVENTION HAS AN ANTIFUNGICIDAL, BACTERICIDAL AND BACTERIOSTATIC ACTIVITY.
Description
United States Patent Int. 01. A611; 27/00 US. Cl. 424-319 1 Claim ABSTRACT OF THE DISCLOSURE An antiseptic composition comprising an aqueous solution of dodecyloxypropylamine-B-butyric acid, dodecylaminopropylamino-[i-butyric acid and an alkyl dimethyl benzyl ammonium chloride, said alkyl having from 8 to 18 carbon atoms, in a weight ratio of 1 to 1 to 0.5, in a pharmacological solvent medium. The antiseptic composition of the invention has an antifungicidal, bactericidal and bacteriostatic activity.
PRIOR APPLICATIONS This application is a streamlined continuation of application Ser. No. 704,946, filed Feb. 12, 1968, now abandoned, which in turn is a streamlined continuation of application Ser. No. 492,839, filed Oct. 4, 1965, now abandoned.
Dodecyloxypropylamino-B-butyric acid is the compound of the formula:
and its molecular weight is 329. It exists in the form of white flakes, which are greasy to the touch and are of bitter taste. It is readily soluble in alcohol, more difficultly soluble in water and practically insoluble in acetone. Its melting point is 121 to 123 C. It is an amphoteric substance and the pH value of a 2% aqueous solution thereof is approximately 5.15. It can be identified by reaction with pyrocatechol and silver oxide, when it gives a violet-tinted pink colouring, and by reaction with ninhydrin, when it causes a violet colouring to develop.
This acid can be prepared by condensing lauryl alcohol with acrylonitrile, reducing the condensation product to the amine and adding crotonic acid to the primary amino group.
-In order to purify the product, it is heated in water to 70 to 80 C. and, on cooling, the acid of low solubility in Water crystallises out (melting point: 122- -l C.); it is washed, centrifuged and dried.
The other essential active ingredient, dodecylaminopropylamino-B-butyric acid, is the compound of the formula: I
and its molecular Weight is 328.
In order to prepare this compound, 1 mol. of dodecylamine can be heated to '60 to 70 C., with 1 mol. of acrylonitrile while stirring constantly for 20 minutes. The mixture is kept for 6 hours at 100 C., then the product is subjected to a hydrogenation in the presence of Raney nickel and ammonia at 130 to 140 C. and under a hydrogen pressure of 150 atm., for 2 hours at the start of ice the operation in order to obtain monododecyl-1,3-arninopropylamine. After elimination of the catalyst by filtration,.the crude product is subjected to fractionated distillation.- The desired product is mixed, in equi-molecular proportions, with crotonic acid, with constant stirring at C. in order to obtain the required amino acid. To purify the acid, the product is dissolved in methyl ethyl ketone on a boiling water bath. The dodecylaminopropylamino-B-butyric acid crystallises on cooling. This is centrifuged and evaporated.
As disclosed above, the composition can optionally contain, as a third principle, an alkyl dimethyl benzyl ammonium chloride. These compounds are disclosed in the United States Pharmacopeia (USP XVI) under the name of benzalkoniurn chloride. They are quaternary ammonium salts containing a benzyl radical, two methyl radicals and a C8H17 to C1gH37 alkyl radical. They exist in the form of amorphous white powders or yellowish gelatinous masses. They have in aromatic odour and a very bitter taste, and are very soluble in water, alcohol, acetone, practically insoluble in ether and slightly soluble in benzene.
The composition provided by the invention may be in the form of an aqueous solution but, in this case, having regard to the low solubility of same of the constituents (and particularly of dodecyloxypropylamino-fl-butyric acid) in Water, the solubilisation is improved by including a physiologically acceptable acid, for example, tartaric acid. The composition may alternatively be in the form of an alcoholic tincture, ointment, gel, milk, liquid, soap, ovule, collutory, nasal, drop or collyrea, etc.
The proportions of the various constituents occurring in the composition can be varied up to the limits imposed by the solubility, but generally preference is given to proportions in the region of 1% of each of the acids and about 0.5% for the benzalkonium chloride.
Using a solution comprising 1% of dodecyloxypropylamino-fl-butyric acid (designated hereinafter by A), 1% of dodecylaminopropylamino-{i-butyric acid (designated hereinafter by -B), and 0.5% of benzalkonium chloride (designated hereinafter by C), and having a pH value equal to 3.9, the following investigations were carried out.
I Bacteriostatic power by diffusion in agar Filter paper discs were impregnated by 0.02 cc. of the solution. The inhibition of the discs, measured as the diameter of inhibition in millimetres for various micro organisms which were used as set out in the following table.
Microorganisms used: A 1% +B 1% +C 0.5
Staphylococcus aureus No. 101 IPL Corynebacterium xerose No. 12 IPL (1/100) 25 Spores of Bacillus subtilis No. 3096 (1/30,000) 22 Klebsiella No. 21 IPL (l/30,000) ll Escherichia coli No. 24 IPL (1/30,000) l5 Pathogenic Escherichia coli No. 111 B4 No. 415
IPL (1/30,000) l5 Salmonella typhi No. 489 IPL 1/30,000 19 Proteus N0. 411 IPL (1/30,000) 0 Pseudomonas aeruginosa (Pyocyanic) No. 725
IPL (1/30,000) 0 Bactericidal power by notation of the surviving elements To study the bactericidal power of a composition according to the invention samples of it were brought into contact in a microbial suspension for times of 1, 5, 10, 30, 60 minutes, 18 hours. After this contact, the microorganisms of the suspension were transplanted onto a solid medium and the percentage of the survivors was evaluated. Using the same solution, which, in the liquid medium, was diluted to a tenth, and the same types of microorganisms as those which served for the study of the bacteriostatic power, it was found that the percentage of surviving elements was zero for the first eleven types of microoranisms after 1 minute. For Proteus No. 411 IPL, it was found that there were 0.1% of surviving elements for a period of contact of 1 minute and no surviving element for longer periods of contact. For Pseudomonas aeruginosea No. 725 IPL, the percentage of surviving elements was equal to 0.01 for a contact time of 1 minute and no surviving element was observed for longer contact times.
Bacteriostatic and bactericidal power by dilution in liquid medium In order to evaluate the bacteriostatic and bactericidal power, a method of dilution in culture broth was used, the solution being distributed in tubes. The first dilution was a 25% dilution and the inhibition after 24 hours in the oven is evaluated.
A sample from each of the tubes which had not grown was transplanted on a new tube of fresh medium (ordinary agar) in order to check the bactericidal activity. The figures expressing the inhibiting dilution for various microorganisms being used are given in the following table.
A 1% plus B 1% plus 0.5%
Microorganisms b B Staphylococcus aureus No. 101 IPL 1/6, 144 1/3, 072 Staphylococcus aureus No. 1060 resistant; to antibiotics 1/6, 144 1 /768 Hemolytic streptococcus Gr. B. No. 6 IPL 1/6, 144 0 Hemolytic streptococcus Gr. A. No. 435 IPL 1/3, 072 0 Streptococcus faecalis (Enteroccos N0. 9 ILP) 1/6, 144 0 Corcuebactcrium :cerose No. 12 IPL. 1/24 0 Spores of Bacillus subtilis No. 3906 IP 1/6, 144 0 Klebsiella No. 21 IPL 1/384 1/96 Pathogenic Escherichia coli No. 415 IPL (III 134).... 1/192 0 Salmonella typhi No. 489 IPL 1/768 0 Proteus No. 411 IPL 1/96 1/6 Pscudemonas aerugiuosa (Pyocyanic) N0. 725 IPL. 1196 1/24 Escherichia coli No. 24 IPL 1/1, 536 11384 b=bacteriostatic power. B =bactericida1 power.
Antifungicidal action For this investigation, liquid Sabouraud medium was used as culture medium, and also a method of dilution in liquid medium. Cultivation took place for eight days at 24 C.
The figures expressing the inhibiting dilution with different types of fungi are given in the following table:
Microorganism b B Candida albicans. 1/1, 096 0 Aspcrgillus m'ger- 1/ 2, 048 0 Rhizopus uigricans 1/1, 024 0 Manor mucedo 0 Tricophyton gypseum 1/4, 096 0 Tricophytou meutagrophytes 1/2, 048 0 anti-inflammatory agents, particularly of the corticoid type, or e-aminocaproic acid.
EXAMPLE 1 An antiseptic was prepared in the form of an aqueous solution, having the following composition:
Dodecyloxypropylamino-fi-butyric acid: 1 g. Dodecylaminopropylamino-fi-butyric acid: 1 g. Benzalkonium chloride: 0.50 g.
Tartaric acid, q.s. for pH 4.20.
Water q.s. for g.
EXAMPLE 2 In similar manner, an alcoholic tincture which can be used as antiseptic had the following composition:
Dodecyloxypropylamino-lS-butyric acid: 1 g. Dodecylaminopropylamino-fi-butyric acid: 1 g. Benzalkonium chloride: 0.50 g.
Erythrosine I (tetraiodofluorescein): 0.05 g. Tartaric acid q.s. for pH 4.20
Alcohol 70 q.s. for 100 g.
For comparing the synergistic properties of the composition according to the invention with the properties of its constituents or partial combinations of its constituents, two series of investigations were carried out with the aid of the following four solutions:
Solution B, which is a 1% solution of dodecylaminopropylamino-fl-butyric acid;
Solution ABC, corresponding to the solution of Example 1;
Solution BC, comprising 1% of dodecylaminopropylaminop-butyric acid and 0.50% of benzalkonium chloride, this solution being at pH 4.20;
Solution C, formed by a 0.50% benzalkonium chloride solution.
Comparison of the bacteriostatic activity of the four solutions.
(1) Staphylococcus pyogenes var. aureus ATCC 6538 P;
(2) Escherichia coli 111 B4 52169, Institut Pasteur, Paris (pathogenic);
(3) Escherichia coli, strain of Faculte de Pharmacie de Paris;
(4) Streptococcus agalactia, group B 55118, Institut Pasteur, Paris (hemolytic);
(5) Streptococcus faecalis GB 5434, Institut Pasteur,
Paris;
(6) Proteus vulgaris, strain of Faculte de Pharmacie.
The results set out in the following table are expressed in cc. of initial solution contained in 1 cc. or agar medium. For example, taking into account successive dilutions, there is observed a bacteriostatic activity with 0.001 cc. of solution per cc. of agar, that is to say, a ratio of 1:1000.
Microorganisms 1 2 3 4 5 6 Solution ABC 1/800 1/50 1/10 1/500 l/250-l/500 1/100 Solution B 1/200 1/50 1/10 1/250 1/100 1/50 Solution BC 1/800 1/50 1/20 1/500 1/100 1/50 Solution 0 1/1, 000 1/20 l/lO 1/500 l/500 1/10 Comparison of the bactericidal activity of the four solutions.
The product to be studied was diluted beforehand in sterile distilled water and the solution obtained was added to a saline peptone broth slightly buttered to pH 7, the broth having been seeded beforehand with a culture of 15/16 hours at 37 C. of the microorganism, diluted to 1/ 10,000.
Generally speaking, the contact between the solution and the microorganism was one hour at ambient temperature. At the end of this period, the number of surviving microorganisms were counted, the counting being effected by placing on agar and reading the colonies which have appeared 15/28 hours after being in the oven at 37 C. The microorganisms investigated were of the same type as those which were used in the comparative study of the bacteriostatic activity The concentration for which it was shown that only 1% of the microorganisms survived was considered as appreciable activity. The concentrations given in the following table are expressed in cc. of initial solution in 1 cc. of medium; for example, if a solution with a dilution of 1/ 100 is still active, the notation is 0.001/ cc. that is to say, a ratio of 1:1000.
Microorganisms. 1 2 3 4 5 6 Solution ABC *1/200 1/100 1/20 1/200 *1/200 1/200 Solution B 1/200 1/10-1/20 1/50-1/100 *1/200 1/100 1/100 Solution BC *1/200 1/100 1/20 *1/200 1/200 1/200 Solution C *1/200 1/100 1/50-1/100 1/100 "1/200 1/50 The products were not tested at higher dilutions.
(d) All these solutions are clearly active against Streptococcus agalactia'e,
(c) The solutions ABC and C are those which are the most active against Streptococcus faecalis,
(f) The solution C has an activity much less than that of the three other solutions against Proteus vulgaris.
As regards the bactericidal activity:
(a) All the solutions are very active against Staphylococcus pyogenes,
(b) The solution B is of a -very low activity against respect to the other three against Escherichia coli,
(c) The solutions BC and ABC are the least active against Escherichia coli (-Fac. Pharm. Paris),
(d) The solution C is clearly less active than the other three against Streptococcus agalactiae,
(e) The solution B is clearly less active than the other three against Streptococcus faecalis,
(f) The solution C is less active than the other three against Proteus vulgaris, the difference being very marked with respect to the solution ABC.
I claim:
1. An antiseptic composition comprising an aqueous solution of dodecyloxypropylamino-;8-butyric acid, dodecylaminopropylamino-[i-butyric acid and alkyl dimethyl benzyl ammonium chloride, said alkyl having from 8 to 18 carbon atoms, in a Weight ratio of about 1 to 1 to 0.5 and tartaric acid sufficient to give a pH in said solution of about 4.2, in a pharmacological solvent media.
References Cited UNITED STATES PATENTS 2,108,765 2/1938 Domagk 424-329 2,113,606 4/1938 Taub 424329 3,039,917 6/1962 vSchmitz 424-319 FOREIGN PATENTS 1,045,601 12/1958 Germany 424-319 JEROME D. GOLDBERG, Primary Examiner U .8. Cl. X.R. 424329
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR990499A FR3997M (en) | 1964-10-06 | 1964-10-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
US3574850A true US3574850A (en) | 1971-04-13 |
Family
ID=8839769
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US871753A Expired - Lifetime US3574850A (en) | 1964-10-06 | 1969-10-07 | Medicament having particularly an antifungal bactericidal and bacteriostatic activity |
Country Status (6)
Country | Link |
---|---|
US (1) | US3574850A (en) |
BE (1) | BE670234A (en) |
FR (1) | FR3997M (en) |
GB (1) | GB1119355A (en) |
IL (1) | IL24395A (en) |
NL (1) | NL6512924A (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4224319A (en) * | 1979-07-31 | 1980-09-23 | Ernest Marcadet | Antiseptic composition for topical application to the skin |
US4481219A (en) * | 1981-07-16 | 1984-11-06 | National Research Development Corporation | Inhibition of growth in fungi |
-
1964
- 1964-10-06 FR FR990499A patent/FR3997M/fr not_active Expired
-
1965
- 1965-09-28 BE BE670234D patent/BE670234A/xx unknown
- 1965-09-28 GB GB41239/65A patent/GB1119355A/en not_active Expired
- 1965-10-01 IL IL24395A patent/IL24395A/en unknown
- 1965-10-06 NL NL6512924A patent/NL6512924A/xx unknown
-
1969
- 1969-10-07 US US871753A patent/US3574850A/en not_active Expired - Lifetime
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4224319A (en) * | 1979-07-31 | 1980-09-23 | Ernest Marcadet | Antiseptic composition for topical application to the skin |
US4481219A (en) * | 1981-07-16 | 1984-11-06 | National Research Development Corporation | Inhibition of growth in fungi |
Also Published As
Publication number | Publication date |
---|---|
IL24395A (en) | 1970-10-30 |
NL6512924A (en) | 1966-04-07 |
FR3997M (en) | 1966-03-14 |
BE670234A (en) | 1966-01-17 |
GB1119355A (en) | 1968-07-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4189481A (en) | Antimicrobial compositions | |
CN113491709B (en) | Multifunctional high-efficiency compound disinfectant and preparation method thereof | |
CN109771315A (en) | A kind of disposable hand-wrist bones gel of environment-friendly type and preparation method thereof | |
KR100541271B1 (en) | Antimicrobial compositions for topical use | |
US4217364A (en) | Antimicrobial compositions | |
CN111184675A (en) | No-clean disinfection composition, preparation method thereof and no-clean disinfection gel | |
US3574850A (en) | Medicament having particularly an antifungal bactericidal and bacteriostatic activity | |
WO2020174340A1 (en) | Eutectic menthol-fatty acid combinations for wound healing | |
US3934031A (en) | Certain aminimides used to control bacteria and fungi | |
Baena-Santillán et al. | Comparison of the Antibacterial Activity and Effect on Membrane Permeability of Hibiscus Acid and a Commercial Chlorhexidine Mouthrinse Against Pathogenic Oral Bacteria and Determination of Hibiscus Acid Toxicity | |
Weinstein et al. | The Action of Urea and Some of its Derivatives on Bacteria: I. Bacteriostatic and Bactericidal Effects of Urea and Urethane | |
US4584198A (en) | Therapeutic compositions having antibacteric activity comprising a fraction extracted from camomile flowers and process for the preparation of said fraction | |
US4076744A (en) | Amphoteric surfactants | |
DE3339196A1 (en) | Antimicrobial preservative and disinfectant | |
Subianto et al. | Antibacterial potential of butterfly Pea (Clitoria ternatea) towards Aggregatibacter actinomycetemcomitans in vitr | |
EP0892785A4 (en) | ||
Ostrolenk et al. | A bactericidal spectrum of some common organisms | |
US20080262082A1 (en) | Composition containing s-(-)-tulipalin b or acetylated-s-(-)-tulipalin b | |
US3934030A (en) | Certain aminimides used to control bacteria and fungi | |
RU2359455C1 (en) | Biocidal composition for skin processing | |
JP7153969B1 (en) | antibacterial agent | |
CN117567270B (en) | Alcohol amine-azelaic acid supermolecule ionic salt and preparation and application thereof | |
CN114344229A (en) | Natural plant bacteriostatic no-clean disinfectant and preparation method and application thereof | |
EP4427729A1 (en) | Preservative for external skin application comprising magnolol, honokiol, or combination thereof, and cosmetic composition comprising same | |
Boakye-Yiadom | Antimicrobial Properties of Some West African Medicinal Plants: I. Antimicrobial Action of Bryophylum pinnatum Lam.(Crassulaceae) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: EXPANCHIMIE, 77 BD MISSION MARCHAND 92400 COURBEVO Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNOR:EXPANSCIENCE, A FRENCH CORP.;REEL/FRAME:004509/0039 Effective date: 19860205 |